Another company working on a COVID drug filed to the SEC SPAC documents for an IPO. Within the document a paragraph addresses the 25 un blinded patients blended with the open label results with statistical data points with p<0.0001. In a SEC document??? I am not vouching the veracity, but I would think if you are trying to launch an IPO/SPAC the lawyers would be very careful. I have never heard of the FDA doing something like this, but again it was clearly stated it came from OWS. Sometimes NP gets the initials wrong, perhaps he meant OWS, perhaps OWS has made this their new protocol, but CYDY is not part of OWS, the other company is. And perhaps I don't know what I am talking about.